Counterfeit Drugs
(1999; 61 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentExecutive Summary
Ouvrir ce répertoire et afficher son contenu1. Introduction
Afficher le document2. Overview of the problem
Afficher le document3. Impact on public health
Afficher le document4. Factors facilitating counterfeiting
Ouvrir ce répertoire et afficher son contenu5. Developing national strategies
Ouvrir ce répertoire et afficher son contenu6. Specific measures
Ouvrir ce répertoire et afficher son contenu7. Assessment of the problem at the national level
Fermer ce répertoire8. Inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard
Afficher le document8.1 Broad objective
Afficher le document8.2 Standard operating procedures (SOP)
Afficher le document8.3 Counterfeit products
Ouvrir ce répertoire et afficher son contenu9. Test methods
Ouvrir ce répertoire et afficher son contenu10. Developing training programmes: inspection and examination of counterfeit pharmaceuticals
Afficher le document11. Conclusion
Afficher le documentReferences
Afficher le documentSelected further reading
Afficher le documentAcknowledgements
Afficher le documentGlossary
 

8.3 Counterfeit products

The following applies specifically to counterfeit products:

- When examining a possible counterfeit pharmaceutical product the inspector shall first screen the product by looking, smelling, touching and listening to the sound of me packing and its contents. The inspector shall look for anything, in particular its labelling and packing, that makes the product look different from an original reference sample. A SOP may assist in examining the product in this way.

- When the organoleptic examination does not give conclusive evidence the inspector shall have a sample tested using appropriate simple screening methods, such as the basic tests recommended by WHO or a suitable thin-layer chromatography method.

- In addition to any full analytical testing, the drug regulatory authority of the country of origin stated on the label of the product may be asked to establish whether the product is counterfeit.

- Proven cases of counterfeit pharmaceutical products shall be fully documented and communicated to all other inspectors, to increase their level of expertise. Information on counterfeit products shall also immediately be made available to drug regulatory authorities of other countries concerned and to WHO.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 24 avril 2012